FDA grants Emergency Use Authorisation for baricitinib in hospitalised COVID-19 patients nine months after initial hypothesis was published by BenevolentAI - Seite 2

The ACTT-2 randomised control trial included more than 1,000 patients. It began on May 8 to assess the efficacy and safety of baricitinib plus remdesivir versus remdesivir alone in hospitalised patients with COVID-19 and was conducted in 8 countries, including the UK.

Media enquiries

Rajin Kang
[e-mail] 
07 71 78 32 880

Note to editors: Baricitinib is approved for the treatment of rheumatoid arthritis and other diseases. It is administered orally and has been used to treat COVID-19 patients in more than 14 clinical trials worldwide, including a randomised clinical trial by NIAID. Eli Lilly is conducting a Phase 3 randomised, double-blind, placebo-controlled study (COV-BARRIER) to evaluate the efficacy and safety of baricitinib in hospitalised adults with COVID-19.

BenevolentAI's research on baricitinib as a treatment for COVID-19 has been published in The Lancet, The Lancet Infectious Diseases, EMBO Molecular Medicine, and Science Advances.

About BenevolentAI (www.benevolent.com)

BenevolentAI creates and applies AI and machine learning to transform the way medicines are discovered and developed. Benevolent integrates its technology into every step of the drug discovery process, from hypothesis generation to early-stage clinical development. BenevolentAI is headquartered in London with a research facility in Cambridge (UK) and an additional office in New York. BenevolentAI has active R&D drug programmes in disease areas such as Amyotrophic Lateral Sclerosis, Ulcerative Colitis and Glioblastoma and has research and commercial collaborations with AstraZeneca and Novartis.